|Bid||5.16 x 800|
|Ask||5.17 x 1400|
|Day's Range||5.04 - 5.33|
|52 Week Range||1.70 - 5.36|
|Beta (3Y Monthly)||-0.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.25|
Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).
BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.
On a per-share basis, the Raleigh, North Carolina-based company said it had a loss of 10 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
BELBUCA® prescription growth further accelerated to an all-time high during the fourth quarter Company increases Belbuca 2019 net sales expectations to $80-$85 million Operating cash flow to become positive ...
NEW YORK, NY / ACCESSWIRE / March 14, 2019 / BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March ...
Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.
BOSTON, March 12, 2019 -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether BioDelivery.
Alnylam (ALNY) submits a CTA application to The Medicines and Healthcare products Regulatory Agency in the United Kingdom for ALN-AGT for the treatment of uncontrolled hypertension.
Every investor in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companiesRead More...
Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
After a disappointing 2018, in which all the three major stock indexes closed in the red owing to severe volatility, Wall Street has made a spectacular comeback this year.
BioSpecifics (BSTC) is expected to provide updates on Xiaflex and its pipeline candidates in its fourth quarter earnings call.
During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.
Zacks.com featured expert Kevin Matras highlights: First, Clearfield, BioDelivery Sciences International, MGIC Investment and Kratos Defense & Security Solutions